|
|
You are searching for "CFAMM00376643" in compound. Total 1 results found.
Click on CFAM IDs and names to search or view in CFAM, click on external IDs to view the entity in its source database.
CFAM Mol ID | CFAMM00376643 |
Family | CFFBM7034 RAC-alpha serine/threonine-protein kinase inhibitor 2-[(4-chlorophenyl)methyl]-1-[4-[(5S)-5-methyl-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl]piperazin-1-yl]-3-(propan-2-ylamino)propan-1-one family |
Superfamily | CFSBM4004 Mitogen-activated protein kinase 9 and Mitogen-activated protein kinase 8 Binder Superfamily |
Class | CFCBM1469 Class 4519 |
External ID | CHEMBL1632380 |
External Source | CHEMBL |
PubChem CID |
53326722 |
Functional Category |
Bioactive |
Molecule Name |
2-[(4-chlorophenyl)methyl]-1-[4-[(5S)-5-methyl-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl]piperazin-1-yl]-3-(propan-2-ylamino)propan-1-one |
IUPAC Name |
2-[(4-chlorophenyl)methyl]-1-[4-[(5S)-5-methyl-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl]piperazin-1-yl]-3-(propan-2-ylamino)propan-1-one |
Synonyms |
CHEBI:1155471 |
InChi |
InChI=1S/C24H32ClN5OS/c1-16(2)26-13-19(12-18-4-6-20(25)7-5-18)24(31)30-10-8-29(9-11-30)23-22-17(3)32-14-21(22)27-15-28-23/h4-7,15-17,19,26H,8-14H2,1-3H3/t17-,19?/m0/s1 |
InChiKey |
KTOSTKQYNJBYHF-KKFHFHRHSA-N |
Formula | C24H32ClN5OS |
Molecular Weight | 474.06 |
Cross Link | CHEMBL1632380 |
Structure |
|
Statistics of CFAM Database |
CFAM currently contains 490,279 molecules in 87,136 families, 34,880 superfamilies and 11,643 classes. |
How to cite our database |
C. Zhang, L. Tao, C. Qin, P. Zhang, S.Y. Chen, X. Zeng, F. Xu, Z. Chen, S.Y. Yang and Y.Z. CFam: A Chemical Families Database Based on Iterative Selection of Functional Seeds and Seed-Directed Compound Clustering.
Nucl. Acids Res. 43 (D1): D558-D565 (2015) (First published online: November 20, 2014).
|
Last update by |
2014.08.29
|
48693 visits since 2014 .........
Dr.
Chen Yuzong
Deputy
Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore
All rights reserved.
|